

Biotechnology


Managing Risk and Financing in Agribusiness Value Chains

Larissa Taylor Senior Manager Agribusiness Consulting & Research Services Rabo Australia Ltd

> Australian Agribusiness Congress 9th September 1999

Global agribusiness is changing rapidly

- Competition between value chains
- Power in value chains evolving to genetics and brands




Momentous year for biotechnology, globally and in Australia

Developments include:

- Cargill and Monsanto glob al biotech joint venture "Reness en"
- Australian labelling of GMO foods
- Consumer concerns: Australian Consensus Conference
- Australian Office of Gene Technology Regulator
- GMO "audits" for supermarket chains
- Media images of GMO crop destruction

Progress of modern biotechnology



Rabobank global trends in food and fibre value chains

- Deregulation
- Trade liberalis ation
- Privatis ation
- Demand sophistication (decommoditisation)
- Market transparency
- Scientific and technological innovation

Definition of biotechnology

"The primary aim of modern biotechnology is to make a living cell perform a specific useful task in a predictable and controlled way"

- Input traits supply and producer oriented
- Output traits demand and consumer oriented





Value drivers of biotechnology

- Strong scientific knowledge base
- Mature capital base
- R&D pipelines
- Product portfolios
- Superior management

Australia's position globally

	\mathbb{C}
\bigcirc	C
	\subset
\bigcirc	\bigcirc
\bigcirc	0

Comparative industries for biotechnology

- Pharmaceutical, chemicals, IT&T
- Partnership along value chains essential
- Is science not marketing itself to consumers? Is capital base not supporting science?

Anticipate the unexpected

- "Pandora's Box" and "Frankenstein"
- What industry are you in?
- Not your direct competitors!
- Firm boundaries: own, control or influence?
- The "Honda Factor"

Growth from the R&D pipeline

- Value Firm = Value Present Assets + Value Growth V_f = V_a + V_g
- Biotech = risk + equity + debt + time
- Biotech = pressure for funding = Australian funding base immature

Biotech funding sources according to risk

- Internal cash flows
- Individual equity
- Venture capital
- Institution al investors
- R&D syndicate
- Public listing
- Debt finance

Equity / Debt













Difficult to price risk in biotechnology

How do financiers price risk?

- Valuing intangible assets
- Securing intangible assets
- Relationship risk along a value chain
- Regulatory risk
- Consumer risk
- Environmental risk

Implications for food and fibre value chains

- Understand the end-user customer
- Understand the value chain
- The "Flav Savr" story
- Financiers with sectoral knowledge
- Successful biotechnology through partnerships